Nerve cell, computer artwork.
Our Work

Latham & Watkins Advises NewLimit on Its US$40 Million Series A Financing

May 22, 2023
Funding will support the company’s work to treat diseases and reverse aging.

NewLimit, a biotechnology company focused on combatting aging through cell biology, genomics, machine learning, and cellular reprogramming, has announced that it has raised US$40 million in a Series A funding round from Dimension, Founders Fund, and Kleiner Perkins with participation from Eric Schmidt, Elad Gil, Garry Tan, and Fred Ehrsam. This new funding is in addition to the founders’ original US$110 million commitment to the company.

Latham & Watkins LLP represented NewLimit in the financing with an emerging companies team led by Bay Area partner Benjamin Potter, with San Diego associate Christian Hollweg. Advice was also provided on intellectual property and data privacy matters by Bay Area partner Jekkie Kim, with associate Michelle Chern; and on benefits and compensation matters by Bay Area partner Ashley Wagner.